Maria Sainz, Pulse Biosciences (PLSE) director, files Form 3 reporting no share ownership

Rhea-AI Filing Summary

Pulse Biosciences, Inc. director reports no share ownership

Maria Sainz, a director of Pulse Biosciences, Inc., filed an initial Form 3 reflecting her position with the company as of 01/08/2026. The filing states that no non-derivative or derivative securities of Pulse Biosciences are beneficially owned.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sainz Maria

(Last) (First) (Middle)

C/O PULSE BIOSCIENCES, INC.

3957 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Kenneth B. Stratton, as Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Pulse Biosciences (PLSE) Form 3 for Maria Sainz report?

The Form 3 for Maria Sainz reports her status as a director of Pulse Biosciences, Inc. as of 01/08/2026. It further states that she does not beneficially own any securities of the company.

Does Maria Sainz own any Pulse Biosciences (PLSE) shares according to this Form 3?

According to this Form 3, no securities are beneficially owned by Maria Sainz. Both the non-derivative and derivative securities tables are effectively empty, and the remarks section explicitly confirms zero beneficial ownership.

What is the relationship of Maria Sainz to Pulse Biosciences (PLSE)?

The filing identifies Maria Sainz as a director of Pulse Biosciences, Inc. She is not listed as an officer or 10% owner in this document, and no other roles are indicated in the relationship section.

What is the event date on Maria Sainz’s Pulse Biosciences (PLSE) Form 3?

The Form 3 shows an event date of 01/08/2026. This date indicates when the status that required the filing, such as becoming a director, became effective for reporting purposes under Section 16 rules.

Are there any transactions reported in this Pulse Biosciences (PLSE) Form 3?

No transactions are reported in this Form 3. The filing is an initial beneficial ownership report and, combined with the statement that no securities are beneficially owned, indicates no acquisitions or holdings to disclose.